No Data
Guangxi Wuzhou Zhongheng Group (600252.SH): The public solicitation of some shares of Chongqing Lummy Pharmaceutical is temporarily suspended.
On December 27, Gala Exchange reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that on December 13, 2024, it disclosed the "Announcement on the Public Collection of Buyers for the Proposed Agreement Transfer of Shares of Chongqing Lummy Pharmaceutical Co., Ltd." on the Shanghai Stock Exchange website. The company plans to transfer 247,426,064 unrestricted circulating A-share stocks of Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical"), which accounts for 23.43% of Lummy Pharmaceutical's total share capital, through a public collection of buyers.
Further Weakness as Chongqing Lummy Pharmaceutical (SZSE:300006) Drops 13% This Week, Taking Three-year Losses to 33%
Dragon and Tiger List | Funds rush into copper cables! Broadex Technologies, Roshow Technology, Shenzhen Woer Heat-shrinkable Material are bought, while 0.302 billion yuan escapes Shanghai Phoenix Enterprise.
The top net purchase amounts on the Dragon and Tiger list for the day were for Broadex Technologies, Roshow Technology, Raisecom Technology, Shenzhen Woer Heat-shrinkable Material, Verisilicon Microelectronics (Shanghai) Co., Ltd., and Kingsignal Technology.
Guangxi Wuzhou Zhongheng Group (600252.SH) subsidiary Chongqing Lummy Pharmaceutical participated in the tenth batch of national Pharmaceutical centralized procurement is expected to be selected.
Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "...")
Chongqing Lummy Pharmaceutical (300006.SZ): Nimodipine injection is expected to be selected for centralized procurement.
On December 13, Gelonghui reported that Chongqing Lummy Pharmaceutical (300006.SZ) announced its participation in the bidding process for the tenth batch of national centralized pharmaceutical procurement organized by the National Joint Procurement Office (referred to as the 'Joint Procurement Office'). According to the 'Public Announcement of the Proposed Results for National Centralized Pharmaceutical Procurement' released by the Joint Procurement Office, the company's product, Nimodipine Injection, is proposed to be selected for this centralized procurement, with a proposed selection price of 3.90 yuan per bottle.
Chongqing Lummy Pharmaceutical (300006.SZ): The controlling shareholder plans to transfer part of the company's shares through an agreement and is publicly soliciting transferees.
Gelonghui reported on December 12 that Chongqing Lummy Pharmaceutical (300006.SZ) announced that its controlling shareholder Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as "Zhongheng Group") intends to transfer its 247,426,064 shares of unrestricted circulating A-shares through a public solicitation of transferees, accounting for 23.43% of the company's total share capital. The transfer price will not be less than the arithmetic average of the daily weighted average price of the 30 trading days prior to the announcement, which is 4.42 yuan/share. The implementation of this public solicitation transfer may result in changes to the company's controlling shareholder and actual controller.
Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) Popularity With Investors Under Threat As Stock Sinks 28%
